National Pension Service Sells 369,502 Shares of Hologic, Inc. $HOLX

Key Points

• The National Pension Service decreased its stake in Hologic, Inc. by 89.3%, holding only 44,480 shares after selling 369,502 shares in the first quarter.
• Hologic reported $1.08 EPS for the latest quarter, slightly surpassing the consensus estimate of $1.05, with quarterly revenues reaching $1.02 billion.
• Analyst ratings for Hologic show a mix of sentiments, with Citigroup upgrading the stock to a "buy" and raising its price target significantly from $60.00 to $80.00.

National Pension Service reduced its stake in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 89.3% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 44,480 shares of the medical equipment provider's stock after selling 369,502 shares during the period. National Pension Service's holdings in Hologic were worth $2,748,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. CANADA LIFE ASSURANCE Co boosted its holdings in Hologic by 4.8% in the fourth quarter. CANADA LIFE ASSURANCE Co now owns 276,408 shares of the medical equipment provider's stock valued at $19,912,000 after acquiring an additional 12,695 shares during the last quarter. Commerce Bank increased its position in shares of Hologic by 2.5% during the fourth quarter. Commerce Bank now owns 12,243 shares of the medical equipment provider's stock worth $883,000 after buying an additional 294 shares during the period. Forum Financial Management LP acquired a new stake in shares of Hologic during the fourth quarter worth $324,000. First Trust Advisors LP raised its stake in Hologic by 75.5% during the fourth quarter. First Trust Advisors LP now owns 308,979 shares of the medical equipment provider's stock worth $22,274,000 after buying an additional 132,943 shares during the last quarter. Finally, Dimensional Fund Advisors LP lifted its holdings in Hologic by 6.9% in the fourth quarter. Dimensional Fund Advisors LP now owns 2,625,290 shares of the medical equipment provider's stock valued at $189,264,000 after buying an additional 169,427 shares during the period. 94.73% of the stock is owned by institutional investors and hedge funds.

Hologic Stock Up 1.4%

Shares of NASDAQ:HOLX traded up $0.94 during mid-day trading on Wednesday, hitting $68.76. 1,890,938 shares of the company traded hands, compared to its average volume of 2,791,663. The stock has a market cap of $15.29 billion, a P/E ratio of 28.53, a P/E/G ratio of 2.44 and a beta of 0.49. The stock has a 50-day moving average price of $65.71 and a two-hundred day moving average price of $62.50. Hologic, Inc. has a 12-month low of $51.90 and a 12-month high of $84.39. The company has a current ratio of 3.55, a quick ratio of 2.81 and a debt-to-equity ratio of 0.52.

Hologic (NASDAQ:HOLX - Get Free Report) last posted its earnings results on Wednesday, July 30th. The medical equipment provider reported $1.08 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.05 by $0.03. The firm had revenue of $1.02 billion during the quarter, compared to analyst estimates of $1.01 billion. Hologic had a net margin of 13.79% and a return on equity of 19.69%. The business's revenue was up 1.2% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.06 EPS. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS. On average, equities research analysts forecast that Hologic, Inc. will post 4.28 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of analysts have weighed in on the company. Argus upgraded Hologic from a "hold" rating to a "buy" rating and set a $80.00 price target for the company in a report on Monday. Raymond James Financial reiterated an "outperform" rating and issued a $71.00 target price (down from $90.00) on shares of Hologic in a report on Friday, May 2nd. Wall Street Zen lowered Hologic from a "buy" rating to a "hold" rating in a research note on Monday, May 5th. Royal Bank Of Canada raised shares of Hologic from a "sector perform" rating to an "outperform" rating and raised their price objective for the stock from $72.00 to $87.00 in a research report on Wednesday, August 6th. Finally, Evercore ISI boosted their target price on shares of Hologic from $62.00 to $68.00 and gave the company an "in-line" rating in a research report on Tuesday, July 8th. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and eight have given a Hold rating to the company's stock. According to MarketBeat.com, Hologic currently has an average rating of "Moderate Buy" and a consensus price target of $78.00.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.